Compare Abeona Therapeutics Inc (ABEO) vs Verisign, Inc. (VRSN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Verisign, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Verisign, Inc. trades at $269.23 (market cap $24.28B). The key difference: Verisign, Inc. is far larger — about 65× Abeona Therapeutics Inc's market cap, and Verisign, Inc. pays a 1.21% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | VRSN | |
|---|---|---|
Market Cap | $373.32M | $24.28B |
Sector | Health | Technology |
52-Week High | $7.23 | $310.00 |
52-Week Low | $4.17 | $211.49 |
Enterprise Value | $228.22M | $25.52B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
VeriSign (VRSN) trades at $266.78, up 4.04% on the day, with a bearish technical signal and mixed earnings history including a Q1 2026 beat. The stock shows strong fundamentals with 49.96% net income margin and $825.7M net income for 2025, though negative shareholder equity remains a concern. Recent news highlights AI-driven domain growth and upcoming Q2 2026 earnings.
Outlook is cautiously optimistic with 57% analyst buy ratings and a $327.67 consensus target offering 23% upside. Key risks include contract renewals, AI disruption potential, and high debt levels. Revenue growth stability and margin strength support investment case, but technical resistance near $266 requires monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
